Hasserjian Robert P
Department of Pathology, WRN 244, Massachusetts General Hospital, Boston, USA.
Best Pract Res Clin Haematol. 2021 Mar;34(1):101249. doi: 10.1016/j.beha.2021.101249. Epub 2021 Feb 6.
The current World Health Organization (WHO) Classification of acute myeloid leukemia (AML), developed in 2016 and published in 2017, codifies the defining features of AML and recognizes several subtypes based on clinical, morphologic, and genetic features. This classification is widely used for the purposes of assigning patients to specific therapeutic approaches and entry into clinical trials. Although the WHO Classification ultimately has its origins in the original 1976 French-American-British Classification, it has been periodically updated by the incorporation of a large body of evidence and input from both diagnosticians and clinicians who study and treat AML. Nevertheless, the recent accumulation of genetic data on the molecular underpinnings of myeloid neoplasms as well as numerous recently approved novel therapies have highlighted areas of controversy in how we currently define and classify AML; the 2016 WHO Classification will continually be revised and updated in future versions based on these advances. The purpose of this review is to explore areas of potential refinement in the current WHO Classification of AML, both in terms of its criteria defining the disease as well as the specific disease subtypes.
当前的世界卫生组织（WHO）急性髓系白血病（AML）分类于2016年制定并于2017年发布，它编纂了AML的定义特征，并根据临床、形态学和遗传学特征识别出几种亚型。这种分类广泛用于将患者分配到特定治疗方法以及进入临床试验的目的。虽然WHO分类最终起源于1976年最初的法美英分类，但通过纳入大量证据以及来自研究和治疗AML的诊断医生和临床医生的意见，它得到了定期更新。然而，最近关于髓系肿瘤分子基础的遗传数据积累以及众多最近批准的新型疗法凸显了我们目前在定义和分类AML方面存在争议的领域；基于这些进展，2016年WHO分类将在未来版本中不断修订和更新。本综述的目的是探讨当前WHO AML分类中潜在的细化领域，包括其定义疾病的标准以及特定疾病亚型。
